Previous Article | Next Article ![]()
Journal of Virology, June 2001, p. 5425-5428, Vol. 75, No. 11
INSERM Unite 380, Laboratoire de
Génétique et Pathologie Expérimentales, Institut
Cochin de Génétique Moléculaire, 75014 Paris,1 and Université Paris
7-Denis Diderot, UFR de Biochimie, 75005 Paris,2 France
Received 15 November 2000/Accepted 23 February 2001
Seven mutations in the C2, V3, and C3 regions of gp120 are
implicated in the tropism of the first CD4-independent human
immunodeficiency virus type 1 isolate, m7NDK. Site-directed mutagenesis
revealed that three amino acids are essential to maintain this tropism, one in the C2 region and two in the V3 loop. Two mutations implied N
glycosylation modifications.
The human immunodeficiency virus
(HIV) enters its target cells after interaction of its gp120
with cellular receptors. The first step implies CD4 binding, which
induces conformational changes in gp120 (23). This
allows it to interact with a coreceptor belonging to the
family of hepta-spanning, transmembrane G-coupled chemokine
receptors, the two well-characterized ones in vivo being CXCR4 and CCR5 (1, 7). Conformational changes
in the V1/V2 and V3 regions of gp120 seem to be implicated in the
exposition of coreceptor binding sites (2, 22, 25, 27,
28).
However, CD4-independent isolates have been characterized: primary or
laboratory-adapted X4- or R5-dependent HIV-2 (6, 11, 20,
21), laboratory-adapted, forced HIV-1 X4 (13) or R5
(15) viruses, and a naturally derived, HIV-1 X4
laboratory-adapted isolate, m7NDK. m7NDK is the first CD4-independent
HIV-1 isolate, and it was characterized in our laboratory
(10). Since these viruses are CD4 independent,
direct interactions between gp120 and the coreceptor might allow
virus entry (10, 13, 19). Our aim was to analyze the role
of each of the mutations of the m7NDK isolate in this interaction.
Since seven mutations in the C2, V3, and C3 regions of the
env gene are responsible for the phenotype change in the
m7NDK isolate (10), we performed site-directed mutagenesis
to revert, one by one, each of the mutated amino acids (Fig.
1). For each reverted mutation, we used
overlap extension PCR to introduce the mutated base
(18). Mutated amplified fragments were then digested using
ScaI and HindIII restriction enzymes and
cloned in the context of the wild-type NDK (wtNDK)
env gene digested by the same enzymes. Those env
genes were then cloned in an expression vector (10). As a
positive control for CD4 independence, the C2, V3, and C3 regions of
the m7NDK env gene were inserted into the
ScaI-HindIII sites of the wtNDK
virus env gene. Using this strategy, all env
genes differed only by the mutation introduced.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.11.5425-5428.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Determination of Essential Amino Acids Involved in the
CD4-Independent Tropism of the X4 Human Immunodeficiency Virus Type
1 m7NDK Isolate: Role of Potential N Glycosylations in the C2
and V3 Regions of gp120


![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References

View larger version (12K):
[in a new window]
FIG. 1.
Comparison of amino acids of the C2, V3, and C3 regions
of the wtNDK and m7NDK HIV-1 isolates. Amino acid differences
are in boldface, and dashes indicate identical amino acids. Positions
of the reverted mutations and the different substitutions and their
positions are indicated and numbered according to the HIV-1
wtNDK Env sequence.
HEK293 cells were then transfected by each Env expression vector
by using the calcium phosphate coprecipitation technique (5). Forty-eight hours later, transfected cells were
trypsinized and mixed (ratio, 1:1) with
HeLaLTRLacZ CD4-positive (P42) or CD4-negative (Z24) indicator cells (9) to analyze
fusion efficiencies. CD4-independent fusion was measured 24 h
later using a CPRG (chlorophenol red-
-D-galactopyranoside) test (Roche) as previously
described (10). For each mutated Env, CD4-independent
fusion efficiencies were compared to either those obtained with
the CD4-independent control (100% CD4 independent), i.e.,
the C2, V3, and C3 regions of m7NDK virus cloned in the
wtNDK Env protein, or those obtained with the wtNDK
Env protein (0% CD4 independent). CD4-independent fusion
efficiencies were estimated as the ratio of
A570 measured with
HeLaLTRLacZ CD4-negative cells
(P42)/A570 measured with
HeLaLTRLacZ CD4-positive cells (Z24). The
result obtained with the CD4-independent control was
defined as 100% and was identical to that obtained with the complete
m7NDK Env protein (data not shown). We first observed that all Env
proteins induced syncytium formation with CD4-positive indicator cells
at an equivalent efficiency (data not shown). As expected, compared to
the CD4-independent control, the wtNDK Env protein presented
a CD4-independent fusion efficiency lower than 5%. Each of the
reverted mutations in the C2, V3, and C3 regions of the m7NDK
env gene led to a decrease of at least twofold in
CD4-independent fusion efficiency (Fig.
2A). This signifies that all amino acids
in the m7NDK C2, V3, and C3 regions of gp120 are necessary for
providing an optimized CD4-independent fusion. However, they could be
classified into three groups: (i) mutants N297Y (Asn at position 297 was mutated into Tyr) and V333A, which presented two- or
threefold-lower (33 and 46% efficiency, respectively) CD4-independent
fusion efficiencies than the CD4-independent control, (ii) A195T and
N296K, which presented five- to ninefold-lower (11 and 18%,
respectively) CD4-independent fusion efficiencies than the
CD4-independent control, and (iii) N192D, I298T, and G307R, which
presented 15- to 20-fold-lower (less than 7%) fusion efficiencies than
the CD4-independent control. Mutants N192D, I298T, and G307R thus
presented a CD4-dependent fusion; therefore, we focused on these three
mutants in the work that followed.
|
The G307R mutation in m7NDK gp120 changes a small and uncharged amino acid (Gly) to a large and charged one (Arg). We therefore changed the Gly into another positively charged (G307K), negatively charged (G307E), or nonpolar (G307A) amino acid (Fig. 1). We observed that the introduction of a charged, either positive or negative, amino acid led to a strictly CD4-dependent fusion phenotype (0 and 2% of CD4-independent fusion efficiency, respectively; Fig. 2B, group 1). Furthermore, introduction of an alanine led to a drastic reduction in CD4-independent fusion efficiency (16%; Fig. 2B, group 1). As all changes had a major influence on the CD4-independent fusion efficiency, we supposed that the CD4-independent tropism required exclusively a noncharged small amino acid at position 307 of the Env protein.
The two other mutations (N192D and I298T) potentially implied modifications of N glycosylation sites (14). Indeed, the N192D reversion eliminated a potential N glycosylation site in the m7NDK C2 region (Fig. 1). We thus mutated this consensus site without modifying the N192 amino acid. We created S194A (no N glycosylation site) and S194T (N glycosylation site) (Fig. 1). We observed that the S194A mutant presented a CD4-independent fusion efficiency more than 10-fold less than that of m7NDK gp120 (9%), whereas a 31% CD4-independent fusion efficiency was obtained with the S194T mutant (Fig. 2B, group 2). These results strongly suggest that the presence of an N glycosylation site is required in the C2 region at position 192 to allow CD4 independence.
The I298T mutation introduces a potential N glycosylation site (NNT) (14) at position 296. This N glycosylation is not present in either of the wtNDK (KYT) or m7NDK (NNI) gp120 proteins (Fig. 1). As K296N is one of the mutations implicated in CD4-independent tropism, we could not mutate this residue directly. Instead, we created I298L (no N glycosylation site) and I298S (N glycosylation site) mutants (Fig. 1). After transfection and fusion analysis, we observed that I298S presented a strict CD4-dependent tropism (2.5% of the CD4-independent fusion efficiency), whereas the I298L mutant presented a 41% CD4-independent fusion efficiency (Fig. 2B, group 3). We thus concluded that the absence of a potential N glycosylation at this position is a prerequisite for CD4-independent tropism.
To confirm the role of N glycosylation site modification, Western blot
analysis was performed on HEK293 cells expressing the Env proteins by
using a gp120 monoclonal antibody (D7324; Aalto). After washing, bound
antibody was detected using a sheep horseradish peroxidase-conjugated secondary antibody followed by enhanced chemiluminescence (ECL; Amersham). Briefly, cells were lysed (1% NP-40, 150 mM NaCl, 10 mM Tris, and 1 mM DTT with 1/100 protease cocktail inhibitors; Sigma) and mixed with an equal volume of 2×
Laemmli buffer (8). Extracts were then loaded on a 12%
polyacrylamide denaturing gel. Clear differences in migration pattern
could be observed between the CD4-independent control (one N
glycosylation site) and its revertants N192D (no N glycosylation site)
and I298T (two N glycosylation sites) (Fig.
3). Considering that the only difference
in these Env proteins is one mutated amino acid, this clearly
demonstrated that differences in migration pattern are associated with
differences in N glycosylation: in the m7NDK Env protein, residue 192 is N glycosylated whereas residue 298 is not. On the other hand, the
mutation N192D suppresses an N glycosylation site, whereas the mutation
I298T introduces one.
|
We showed that three mutations are essential for maintaining the
CD4-independent phenotype. The first corresponded to a small noncharged
amino acid, namely G307. It is worth noting that this amino acid is in
the GPG consensus motif (GLG in the case of m7NDK gp120) and that the
change occurring in m7DK gp120 is R to G. This motif is probably
situated at the tip of the V3 loop, and it is suspected that it forms a
type II
-turn (3, 4, 12, 26). As the tip sequence of
the V3 domain seems to be implicated in cell tropism (24),
the insertion of an electrostatic charge, as well as the presence of a
side chain with high steric hindrance at position 307, might constrain
the V3 loop conformation and alter CXCR4 binding affinity. On the
contrary, the presence of G307 might lead to a better flexibility of
the V3 loop, thus allowing a direct and efficient interaction with
CXCR4. The two other mutations implied modifications of potential N
glycosylation sites. According to the same logic, the existence of an N
glycosylation at position 296 might interfere with CXCR4 binding,
whereas the N glycosylation in the C2 (amino acid N192) region
might stabilize the open conformation of coreceptor binding site. These
hypotheses are supported by the recent finding that the presence or
absence of a conserved carbohydrate moiety on the V3 region of the
gp120 V3 on clade A and B viruses could modulate the CD4 or
chemokine binding sites (17).
Although a common mechanism may explain the direct interaction between Env and CXCR4, no consensus region can be evidenced between the different CD4-independent isolates, even though most (16, 21) or all (15) of the modifications concern N glycosylation sites. As alternative conformations of the coreceptor binding site have been suggested (2, 22, 25, 27, 28), a consensus explanation would consider that all CD4-independent viruses present a set of mutations which together provide better accessibility to the coreceptor binding site because of a better flexibility of V3 and/or V1/V2 loops. Taken together, our results strongly suggest that mutations in m7NDK gp120 lead to a high-affinity conformation of the coreceptor binding site since the essential mutations we characterized might have consequences on V3 loop conformation.
| |
ACKNOWLEDGMENTS |
|---|
We are grateful for the technical support of A. Miccinilli. Nicolas Boord edited the manuscript. J.D. holds a fellowship from Ministère de l'Education Nationale, de l'Enseignement Supérieur et de la Recherche.
This work was supported by grants from Agence Nationale de la Recherche contre le SIDA (ANRS), "Ensemble contre le SIDA" AO11 and AO2 "Lutte anti-Sida" from the University of Paris 7-Denis Diderot.
| |
FOOTNOTES |
|---|
* Corresponding author: Mailing address: INSERM Unité 380, Laboratoire de Pathologie et Genétique Expérimentales, Institut Cochin de Genétique Moléculaire, 22 Rue Méchain, 75014 Paris, France. Phone: 33-1-40516455. Fax: 33-1-40516407. E-mail: hazan{at}cochin.inserm.fr.
Present address: Microbiology and Immunology Department, Albert
Einstein College of Medicine, Bronx, NY 10461.
Present address: CNRS UMR146, Laboratoire de Régulations
Cellulaires et Oncogénèse, Institut Curie, 91405 Orsay, France.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700[CrossRef][Medline]. |
| 2. | Cao, J., N. Sullivan, E. Desjardin, C. Parolin, J. Robinson, R. Wyatt, and J. Sodroski. 1997. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J. Virol. 71:9808-9812[Abstract]. |
| 3. |
Catasti, P.,
E. M. Bradbury, and G. Gupta.
1996.
Structure and polymorphism of HIV-1 third variable loops.
J. Biol. Chem.
271:8236-8242 |
| 4. |
Catasti, P.,
J. D. Fontenot,
E. M. Bradbury, and G. Gupta.
1995.
Local and global structural properties of the HIV-MN V3 loop.
J. Biol. Chem.
270:2224-2232 |
| 5. |
Chen, C., and H. Okayama.
1987.
High-efficiency transformation of mammalian cells by plasmid DNA.
Mol. Cell. Biol.
7:2745-2752 |
| 6. |
Clapham, P. R.,
A. McKnight, and R. A. Weiss.
1992.
Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4.
J. Virol.
66:3531-3537 |
| 7. | Clapham, P. R., J. D. Reeves, G. Simmons, N. Dejucq, S. Hibbitts, and A. McKnight. 1999. HIV coreceptors, cell tropism and inhibition by chemokine receptor ligands. Mol. Membr. Biol. 16:49-55[CrossRef][Medline]. |
| 8. |
Cleveland, D. W.,
S. G. Fischer,
M. W. Kirschner, and U. K. Laemmli.
1977.
Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis.
J. Biol. Chem.
252:1102-1106 |
| 9. |
Dragic, T.,
P. Charneau,
F. Clavel, and M. Alizon.
1992.
Complementation of murine cells for human immunodeficiency virus envelope/CD4-mediated fusion in human/murine heterokaryons.
J. Virol.
66:4794-4802 |
| 10. |
Dumonceaux, J.,
S. Nisole,
C. Chanel,
L. Quivet,
A. Amara,
F. Baleux,
P. Briand, and U. Hazan.
1998.
Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype.
J. Virol.
72:512-519 |
| 11. | Endres, J. M., P. R. Clapham, M. Marsh, M. Ahuja, J. Davis-Turner, A. McKnight, J. F. Thomas, B. Stoebenau-Haggarty, S. Choe, P. J. Vance, T. N. C. Wells, C. A. Power, S. S. Sutterwala, R. W. Doms, N. R. Landau, and J. A. Hoxie. 1996. CD4-independent infection by HIV-2 is mediated by fusin/CXCR-4. Cell 87:745-756[CrossRef][Medline]. |
| 12. |
Fontenot, J. D.,
J. M. Gatewood,
S. V. Mariappan,
C. P. Pau,
B. S. Parekh,
J. R. George, and G. Gupta.
1995.
Human immunodeficiency virus (HIV) antigens: structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins.
Proc. Natl. Acad. Sci. USA
92:315-319 |
| 13. | Hoxie, J. A., C. C. LaBranche, M. J. Endres, J. D. Turner, J. F. Berson, R. W. Doms, and T. J. Matthews. 1998. CD4-independent utilization of the CXCR4 chemokine receptor by HIV-1 and HIV-2. J. Reprod. Immunol. 41:197-211[CrossRef][Medline]. |
| 14. | Imperiali, B., and S. E. O'Connor. 1999. Effect of N-linked glycosylation on glycopeptide and glycoprotein structure. Curr. Opin. Chem. Biol. 3:643-649[CrossRef][Medline]. |
| 15. |
Kolchinsky, P.,
T. Mirzabekov,
M. Farzan,
E. Kiprilov,
M. Cayabyab,
L. J. Mooney,
H. Choe, and J. Sodroski.
1999.
Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication.
J. Virol.
73:8120-8126 |
| 16. |
LaBranche, C. C.,
T. L. Hoffman,
J. Romano,
B. S. Haggarty,
T. G. Edwards,
T. J. Matthews,
R. W. Doms, and J. A. Hoxie.
1999.
Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity.
J. Virol.
73:10310-10319 |
| 17. |
Malenbaum, S. E.,
D. Yang,
L. Cavacini,
M. Posner,
J. Robinson, and C. Cheng-Mayer.
2000.
The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors.
J. Virol.
74:11008-11016 |
| 18. | Pogulis, R. J., A. N. Vallejo, and L. R. Pease. 1996. In vitro recombination and mutagenesis by overlap extension PCR. Methods Mol. Biol. 57:167-176[Medline]. |
| 19. | Potempa, S., L. Picard, J. D. Reeves, D. Wilkinson, R. A. Weiss, and S. J. Talbot. 1997. CD4-independent infection by human immunodeficiency virus type 2 strain ROD/B: the role of the N-terminal domain of CXCR-4 in fusion and entry. J. Virol. 71:4419-4424[Abstract]. |
| 20. |
Reeves, J. D.,
S. Hibbitts,
G. Simmons,
A. McKnight,
J. M. Azevedo-Pereira,
J. Moniz-Pereira, and P. R. Clapham.
1999.
Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo.
J. Virol.
73:7795-7804 |
| 21. | Reeves, J. D., A. McKnight, S. Potempa, G. Simmons, P. W. Gray, C. A. Power, T. Wells, R. A. Weiss, and S. J. Talbot. 1997. CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. Virology 231:130-134[CrossRef][Medline]. |
| 22. |
Rizzuto, C. D.,
R. Wyatt,
R. N. Hernandez,
Y. Sun,
P. D. Kwong,
W. A. Hendrickson, and J. Sodroski.
1998.
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.
Science
280:1949-1953 |
| 23. |
Sattentau, Q. J.,
J. P. Moore,
F. Vignaux,
F. Traincard, and P. Poignard.
1993.
Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding.
J. Virol.
67:7383-7393 |
| 24. | Shimizu, N., Y. Haraguchi, Y. Takeuchi, Y. Soda, K. Kanbe, and H. Hoshino. 1999. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the Env protein. Virology 259:324-333[CrossRef][Medline]. |
| 25. |
Sullivan, N.,
Y. Sun,
Q. Sattentau,
M. Thali,
D. Wu,
G. Denisova,
J. Gershoni,
J. Robinson,
J. Moore, and J. Sodroski.
1998.
CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.
J. Virol.
72:4694-4703 |
| 26. |
Wu, G.,
R. MacKenzie,
P. J. Durda, and P. Tsang.
2000.
The binding of a gp120 V3 loop peptide to HIV-1 neutralizing antibodies: structural implications.
J. Biol Chem.
275:36645-36652 |
| 27. | Wyatt, R., P. D. Kwong, E. Desjardins, R. W. Sweet, J. Robinson, W. A. Hendrickson, and J. G. Sodroski. 1998. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711[CrossRef][Medline]. |
| 28. | Wyatt, R., J. Moore, M. Accola, E. Desjardin, J. Robinson, and J. Sodroski. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|